The Trump administration has entered into Most Favored Nation Agreements (MFNs) on drug prices with 16 drug manufacturers. According to Securities and Exchange Commission (SEC) filings, some of these agreements expire after three years[1]. Details of the agreements, including their duration, have not been disclosed by either the administration or the companies[1]. The agreements differ for each of the 16 companies, but have several common features[1]. President Trump often claims that these agreements will ensure that the US no longer pays more than is fair for prescription drugs[1]. The article also mentions the controversy surrounding the 340B program, but does not provide further details[original content].